News Conference News EuroPCR 2022 Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO Yael L. Maxwell May 23, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Daily News Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality Michael O'Riordan March 10, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for January 2022 Shelley Wood January 31, 2022
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Daily News Rivaroxaban Again Linked to More Bleeding vs Other DOACs Caitlin E. Cox October 11, 2021
News Conference News ACC 2021 ATLANTIS: Apixaban Has No Benefit Over Standard of Care Post-TAVI Yael L. Maxwell May 15, 2021
News Conference News AHA 2020 Rivaroxaban an Option for Patients with Bioprosthetic Mitral Valves and A-fib Todd Neale November 14, 2020
News Opinion Editor's Corner A ‘Virtual’ ACC 2020? TCTMD Has You Covered, However Things Roll Out Shelley Wood March 16, 2020
News Daily News Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients Michael O'Riordan March 11, 2020
News Daily News Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights Yael L. Maxwell February 28, 2020
News Conference News CRT 2020 Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation Michael O'Riordan February 26, 2020
News Conference News CRT 2020 Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR L.A. McKeown February 24, 2020
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Conference News TCT 2019 Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA Michael O'Riordan September 28, 2019